Alkermes Plc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alkermes Plc. on November 28, 2017. The report addresses a significant legal development regarding the company's intellectual property portfolio involving U.S. Patent Number 6,667,061 (the "'061 Patent").
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific legal event and does not contain financial statements.
Material Changes and Legal Developments
- PTAB Decision: On November 28, 2017, the United States Patent and Trademark Office's Patent Trials and Appeal Board (PTAB) upheld the validity of the '061 Patent.
- Challengers: The patent was challenged via the inter partes review process by Luye Pharma Group Ltd. and its affiliates (collectively "Luye").
- Patent Coverage: The '061 Patent is Orange Book-listed for the products Bydureon, Risperdal Consta, and Vivitrol.
- Next Steps: Luye has 30 days from the entry of the final decision to file a request for rehearing with the PTAB.
Management Commentary, Risks, and Outlook
Alkermes stated it will oppose any attempt by Luye to reverse the PTAB's decision and will continue to vigorously defend the '061 Patent. The filing includes a standard caution regarding forward-looking statements, noting that actual results may differ materially due to various risks and uncertainties described in the company's Form 10-K and Form 10-Q filings.
Key Facts for Investor Verification
- Confirm the status of the 30-day window for Luye to request a rehearing with the PTAB.
- Verify the specific impact of the '061 Patent on the market exclusivity periods for Bydureon, Risperdal Consta, and Vivitrol.
- Monitor subsequent filings for any rehearing requests filed by Luye or further legal proceedings.
- Review the company's most recent Form 10-Q or 10-K for financial context not included in this 8-K.